JP
TEVA icon

Jana Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Jana Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,453,950
Closed -$37.8M – 31
2018
Q4 		$37.8M Sell
2,453,950
-451,626
-16% -$9.26M 1.73% 21
2018
Q3 		$62.6M Sell
2,905,576
-30,231
-1% -$702K 1.9% 15
2018
Q2 		$71.4M Sell
2,935,807
-540,541
-16% -$11M 1.89% 19
2018
Q1 		$59.4M Sell
3,476,348
-106,365
-3% -$2.08M 1.77% 18
2017
Q4 		$67.9M Buy
+3,582,713
New +$53.9M 1.79% 20
2014
Q2 		– Sell
-2,033,131
Closed -$107M – 71
2014
Q1 		$107M Buy
+2,033,131
New +$94M 1.26% 25

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jana Partners's TEVA Position: Q1 2019 in Review

Jana Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 2,453,950 shares — an estimated $37.8M sold.

Jana Partners first reported a position in TEVA in Q1 2014 and held it in 6 quarters. The position peaked at $107M in Q1 2014. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Jana Partners reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Jana Partners sold 2,453,950 Teva Pharmaceuticals shares in Q1 2019, an estimated $37.8M.
  • Jana Partners first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • Jana Partners's Teva Pharmaceuticals position peaked at $107M in Q1 2014.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Jana Partners's 13F filing for Q1 2019, filed 15 May 2019.